ArticleContact dermatitis2021
Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.
Article in Contact dermatitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dupilumab in Inflammatory Skin Diseases: A Systematic Review.Biomolecules · 2023Pooled it
- Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.The British journal of dermatology · 2023Trial
- Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study.Acta dermato-venereologica · 2025Article
- Inflammatory Skin Diseases: The Importance of Immunological Signatures.Deutsches Arzteblatt international · 2025Review
- Chronic Hand Eczema.American journal of clinical dermatology · 2024Review
- Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study.Journal of clinical medicine · 2024Article
- Occupational Hand Dermatitis.Current allergy and asthma reports · 2023Review
- Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review.Journal of asthma and allergy · 2023Article
- The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.Contact dermatitis · 2022Observational
- Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series.Dermatology (Basel, Switzerland) · 2022Article
- Irritant Contact Dermatitis - a Review.Current dermatology reports · 2022Review
- Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.Contact dermatitis · 2021Article
- Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges.Therapeutics and clinical risk management · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.